Matches in SemOpenAlex for { <https://semopenalex.org/work/W2366623685> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2366623685 abstract "Objective:To evaluate the efficacy and adverse reactions of gemcitabine plus cisplatin ( GP ) and docetaxel plus cisplatin ( DP ) in the treatment of advanced non-small-cell lung cancer ( NSCLC ). Methods:Sixty-eight patients with NSCLC selected by certain criteria were divided into 2 groups (group A and B),each group had 34 cases,the inclusive criteria included:ECOG ≤ 2 points,survival time more than three months,WBC counts4.0×109/ L ,normal liver and renal function,no symptoms and signs of active infection,III or Ⅳ stage of pathology. Patients in group A were treated with gemcitabine plus cisplatin (GP) [gemcitabinei(G) 1 000 mg/m2,intravenous infusion,D1,8; cisplatin (P) 80 mg/m2,intravenous infusion,D1-5] and patients in group B were treated with docetaxel plus cisplatin (DP) [docetaxel (D) 75mg/m2,intravenous infusion,D1,cisplatin (P) 80mg/m2,intravenous infusion,D1-5]. The efficacy and adverse reactions were observed and studied. Results:The objective overall response rates of group A and B were 41.2% and 47.1% respectively,the difference between group A and B was not significant(P0.05). The Ⅲ~Ⅳ degree adverse reactions were less than total adverse reactions in the two groups,the incidence of thrombocytopenia in group A was significantly higher than that in group B (P0.05),the incidence of hair loss in group A was significantly lower than that in group B (P0.05); 3 / 4 degree of adverse reactions including local reactions,hair loss,constipation,and peripheral neuritis in group B were significantly higher than that in group A (P0.05),the other 3 / 4 degree of adverse reactions were no significant difference between the group A and B(P0.05). 1-year survival rate in group A and B was 41.2% and 44.1% respectively,the median time to disease progression in group A and B was 5.8 months and 6.1 months respectively. Conclusion:New platinum-based combining chemotherapy,such as GP and DP,has higher efficacy and more safety; it could be a new and better chemotherapy of advanced NSCLC." @default.
- W2366623685 created "2016-06-24" @default.
- W2366623685 creator A5047260001 @default.
- W2366623685 date "2009-01-01" @default.
- W2366623685 modified "2023-09-23" @default.
- W2366623685 title "Evaluation of two kinds of chemotherapy on advanced non-small-cell cancer" @default.
- W2366623685 hasPublicationYear "2009" @default.
- W2366623685 type Work @default.
- W2366623685 sameAs 2366623685 @default.
- W2366623685 citedByCount "0" @default.
- W2366623685 crossrefType "journal-article" @default.
- W2366623685 hasAuthorship W2366623685A5047260001 @default.
- W2366623685 hasConcept C120665830 @default.
- W2366623685 hasConcept C121332964 @default.
- W2366623685 hasConcept C126322002 @default.
- W2366623685 hasConcept C197934379 @default.
- W2366623685 hasConcept C2776694085 @default.
- W2366623685 hasConcept C2777785397 @default.
- W2366623685 hasConcept C2778239845 @default.
- W2366623685 hasConcept C2780258809 @default.
- W2366623685 hasConcept C2780678043 @default.
- W2366623685 hasConcept C2781190966 @default.
- W2366623685 hasConcept C61511704 @default.
- W2366623685 hasConcept C71924100 @default.
- W2366623685 hasConcept C90924648 @default.
- W2366623685 hasConceptScore W2366623685C120665830 @default.
- W2366623685 hasConceptScore W2366623685C121332964 @default.
- W2366623685 hasConceptScore W2366623685C126322002 @default.
- W2366623685 hasConceptScore W2366623685C197934379 @default.
- W2366623685 hasConceptScore W2366623685C2776694085 @default.
- W2366623685 hasConceptScore W2366623685C2777785397 @default.
- W2366623685 hasConceptScore W2366623685C2778239845 @default.
- W2366623685 hasConceptScore W2366623685C2780258809 @default.
- W2366623685 hasConceptScore W2366623685C2780678043 @default.
- W2366623685 hasConceptScore W2366623685C2781190966 @default.
- W2366623685 hasConceptScore W2366623685C61511704 @default.
- W2366623685 hasConceptScore W2366623685C71924100 @default.
- W2366623685 hasConceptScore W2366623685C90924648 @default.
- W2366623685 hasLocation W23666236851 @default.
- W2366623685 hasOpenAccess W2366623685 @default.
- W2366623685 hasPrimaryLocation W23666236851 @default.
- W2366623685 hasRelatedWork W2073426637 @default.
- W2366623685 hasRelatedWork W2347520915 @default.
- W2366623685 hasRelatedWork W2349083402 @default.
- W2366623685 hasRelatedWork W2349209874 @default.
- W2366623685 hasRelatedWork W2350960089 @default.
- W2366623685 hasRelatedWork W2351441972 @default.
- W2366623685 hasRelatedWork W2357024932 @default.
- W2366623685 hasRelatedWork W2358789218 @default.
- W2366623685 hasRelatedWork W2364924529 @default.
- W2366623685 hasRelatedWork W2365343640 @default.
- W2366623685 hasRelatedWork W2365551818 @default.
- W2366623685 hasRelatedWork W2367782282 @default.
- W2366623685 hasRelatedWork W2372636568 @default.
- W2366623685 hasRelatedWork W2372651827 @default.
- W2366623685 hasRelatedWork W2372659919 @default.
- W2366623685 hasRelatedWork W2373053832 @default.
- W2366623685 hasRelatedWork W2373080609 @default.
- W2366623685 hasRelatedWork W2379183281 @default.
- W2366623685 hasRelatedWork W2393617399 @default.
- W2366623685 hasRelatedWork W3029500008 @default.
- W2366623685 isParatext "false" @default.
- W2366623685 isRetracted "false" @default.
- W2366623685 magId "2366623685" @default.
- W2366623685 workType "article" @default.